Novartis AG agreed to buy biotechnology company Avidity Biosciences Inc. in a deal that values it at $12 billion, according to the Swiss drugmaker.

Drugmaker Wyeth this morning said it has acquired a private British biotech company developing medicines in the potentially lucrative field of obesity, in a deal that could be worth up to $150 million ...

The biotechnology giant’s board will front angry investors this week after losing more than a quarter of its market value ...

NEW YORK] Novartis agreed to buy biotechnology company Avidity Biosciences in a deal that values it at US$12 billion, ...